MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
422.50
+16.10
+3.96%
After Hours: 422.50 0 0.00% 19:25 01/07 EST
OPEN
405.51
PREV CLOSE
406.40
HIGH
427.05
LOW
405.51
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
205.87
MARKET CAP
55.82B
P/E (TTM)
1847.40
1D
5D
1M
3M
1Y
5Y
1D
Alnylam assumed with an Outperform at Oppenheimer
TipRanks · 11h ago
Wells Fargo Sticks to Its Hold Rating for Alnylam Pharma (ALNY)
TipRanks · 13h ago
Alnylam price target lowered to $491 from $525 at Bernstein
TipRanks · 1d ago
Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
TipRanks · 1d ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: BERNSTEIN CUTS TARGET PRICE TO $491 FROM $525
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Reuters · 1d ago
Alnylam Pharmaceuticals to Unveil Five-Year Strategy at J.P. Morgan Healthcare Conference
Reuters · 2d ago
Weekly Report: what happened at ALNY last week (1229-0102)?
Weekly Report · 2d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.